Edwards Lifesciences Corporation (NYSE: EW), the global leader in the science of heart valves and hemodynamic monitoring, reported that The New England Journal of Medicine today published results from Cohort B of The PARTNER Trial, which studied the Edwards SAPIEN transcatheter heart valve for the treatment of severe aortic stenosis. The results of the trial successfully met the primary endpoints of all-cause mortality and mortality plus repeat hospitalization.
To view Multimedia News Release, go to http://multivu.prnewswire.com/mnr/prne/edwardslifesciences/44227/
Software just changed the way of our work. First, computer came and changes the technology. Then, Internet changed our way to look for anything and now, hundreds of software launched each day to make our work easier on computers. Number of IT companies from all over the world just keep on developing kind of software which human beings had dream last night and what he got next day. In latest software release news, the software already available on Internet and many of users already gone through all its working. Advanced technology and much explore of human brains made this thing look very easy.
Software somehow makes our work much easier on our working machines. Internet becomes the source to get any software instant if available. Most of the software on the Internet available without any cost and some of them want you to pay before use. Among most of the categories, we mostly come up with two kinds, Commercial and Open Source software. Now, what these kind of software?
Let me to explain about these software types:-
Open Source Software:- Open Source software are those kind of software which requires no cost to use them and anyone seek any kind of improvement software need can improve it and again, launch with its improved version on Internet. Again, another user can add some extra features to that software and launch on the Internet. Programming code for open source software easily available on Internet.
Commercial Software: - Open Source software can also be commercial software. Commercial software used as commercial purposes. Some of this software is available on the Internet for free, while some named software you can also get for free but on a trial period maximum of 30 days. After 30 days of use, you have to purchase the software license. Microsoft, Adobe etc all among these commercial software production companies. Some of the best commercial software made by these multinational companies are MS Office, Adobe Photoshop, Adobe Flash player etc.
Take Linux as most appropriate example. Linux was first launched in 1991 and now, a number of improved versions available on the Internet. Linux is completely open source operating system software. If you have some knowledge about software and want to add some extra features, you can easily do it. Most of the companies currently have Linux as there operating system rather than Windows XP, Windows Vista or Windows 7 because Linux is much easier to operate and occupied less space, light in use. Now, take a look on Adobe Photoshop. You want to make an image, website, background image with some special effects etc, you need to have knowledge about Adobe Photoshop and its various features.
This commercial software somehow available without any cost on Internet but you just cannot go for all its features. You want to use all its features, go and purchase a license. But you do not need to pay for open source software.
Today, Novo Nordisk announced new phase 3 interim data from its guardianTM2 trial for its recombinant coagulation factor VIII (rFVIII) product NovoEight® (turoctocog alfa), the first new rFVIII molecule in over a decade, which shows that it provides long-term reduction from bleeding in people with haemophilia A when used as a preventative treatment.1 The results were presented at the World Federation of Haemophilia (WFH) World Congress and support findings from other studies within the guardianTM clinical programme that found NovoEight® demonstrated good efficacy in preventing and treating bleeds without inhibitor development in previously treated patients.
To view the Multimedia News Release, go to: http://www.multivu.com/mnr/71400529-novoeight-reduction-of-bleeding-haemophilia-a
Boston Scientific Corporation (NYSE: BSX) announces positive clinical data from the Research in Severe Asthma (RISA) Trial, demonstrating the long-term safety of bronchial thermoplasty (BT) in patients treated with the Company’s AlairTM Bronchial Thermoplasty System. Follow-up data demonstrate that stable lung function is maintained and late clinical complications are absent over a five-year period in patients with severe refractory asthma treated with BT. Results were presented today at the annual European Respiratory Society (ERS) Congress in Amsterdam by Michel Laviolette, M.D., Professor of Medicine, Institut universitaire de cardiologie et de pneumologie at Université Laval in Québec City, Canada.
To view Multimedia News Release, go to http://multivu.prnewswire.com/mnr/prne/bostonscientific/52128/
Optimer Pharmaceuticals, Inc. (NASDAQ: OPTR) announced The New England Journal of Medicine has published results from the North American Phase 3 trial evaluating the safety and efficacy of the Company’s novel antibiotic fidaxomicin as a treatment for patients with Clostridium difficile infection (CDI). The Phase 3 trial showed that fidaxomicin significantly reduced recurrence rates and increased global cure rates when compared to vancomycin, the only treatment approved by the U.S. Food and Drug Administration for CDI. The article titled,
http://monitiumworldwide.com
Discover how to create multiple income streams online with this on of a
kind wealth building platform. take your 14 free trial today.
http://www.youtube.com/watch?v=k62uRyp6hiY
http://www.xcart-manager.com Discover Store Manager for X-Cart - the intelligent assistant that helps you to get things done! Save at least 2 hours every day updating your products, categories and attributes in one window. Get a free trial at http://www.xcart-manager.com/download
http://www.oscommerce-manager.com Discover Store Manager for osCommerce - the intelligent assistant that helps you to get things done! Save at least 2 hours every day updating your products, product categories and attributes in one window. Get a free trial at http://www.oscommerce-manager.com/download
http://www.mag-manager.com/magento-quickbooks-integration Extend the functionality of your Store Manager with QuickBooks Integration Addon! Save hours each day and push your business to the next level! Try Store Manager for Magento now! Get a free trial at http://www.mag-manager.com/free-download
http://www.mag-manager.com/magento-quickbooks-integration Extend the functionality of your Store Manager with QuickBooks Integration Addon! Save hours each day and push your business to the next level! Try Store Manager for Magento now! Get a free trial at http://www.mag-manager.com/free-download
World trade in perishable foods turns a page as Maersk Container Industry (MCI), an independent business unit in the Maersk Group conglomerate, today announced that it has begun production of the first refrigerated containers and Star Cool refrigeration machines built in South America at its new MCI facility in San Antonio, Chile.
The first trial production of these ISO standard 40 feet reefer containers were successfully delivered during the third quarter of 2015 into the Maersk Line and CMA CGM operations. Shortly thereafter, both shipping lines placed new orders. To further leverage this new value proposition, Maersk Line has secured a fixed monthly volume from the MCI facility allowing for increased agility and fast response time to the demand in the region.
“In this sweet spot of fruit exporters, we have placed the factory right where the demand is. For the first time ever in South America, reefer containers can go straight “from factory to farm”,” said Stig Hoffmeyer, Chief Executive Officer of MCI. “Offering the Star Cool Integrated reefers locally to shipping lines, farmers, fruit distributors and leasing companies, will have a financial benefit counted in thousands of dollars per reefer, and millions for the industry in total,” he continued.
To view the multimedia release go to:
http://www.multivu.com/players/uk/7688551-maersk-container-industry-factory-chile/
Going on the offensive against one of the most daunting challenges in cancer, The Leukemia & Lymphoma Society (LLS) today announced the launch of a groundbreaking, collaborative clinical trial for acute myeloid leukemia (AML), a deadly disease which has seen few improvements in treatments in more than 40 years.
Beat AML was announced yesterday by Vice President Biden, along with many new, Moonshot inspired initiatives across industry, non-profit and government.
AML is the most lethal of the blood cancers, which together are the third leading cause of cancer deaths in the U.S.; AML is responsible for more than 10,000 deaths each year. Despite advances in treating other blood cancers, the standard of treatment for AML – a combination of toxic chemotherapies – has remained the same for more than 40 years. Overall prognosis remains poor, with a five-year survival rate below 20 percent for patients over age 60.
To view the multimedia release go to:
http://www.multivu.com/players/English/7554854-lls-beat-aml-acute-myeloid-leukemia/
